摘要目的 研究99Tcm-甲氧基异丁基异腈(99Tcm-MIBI)亲肿瘤显像在可手术乳腺癌新辅助化疗疗效及预后预测中的价值.方法 对65例拟行新辅助化疗的可手术乳腺癌患者进行99Tcm-MIBI显像,采集10和180 min两时相的平面像,计算放射性清除率,分析清除率与化疗疗效和患者无病生存率的关系.结果 65例乳腺癌患者99Tcm-MIBI显像的放射性清除率为(17.4±6.8)%.新辅助化疗达完全缓解4例,部分缓解52例,疾病稳定8例,疾病进展1例,有效率为86.2%.新辅助化疗有效组和无效组的放射性清除率分别为(15.5±5.0)%和(29.2±3.2)%,差异有统计学意义(P＜0.001).高清除率组乳腺癌患者的无病生存率(53.1%)显著低于低清除率组(75.8%,P=0.046).结论 99Tcm-MIBI显像清除率可用于可手术乳腺癌新辅助化疗疗效的预测,并具有一定的预后价值.

abstractsObjective To investigate the value of technetium-99m methoxyisobutylisonitrile (99Tcm-MIBI) imaging in predicting the efficacy of neoadjuvant chemotherapy (NCT) and prognosis in patients with operable breast cancer. Methods Sixty five patients with breast cancer underwent 99Tcm-MIBI scintimammography before NCT, and static planar images were taken at 10 min and 180 min after scintimammography. The clearance rate was calculated in each patient, correlation between the clearance rate and efficacy of NCT, and the disease free survival rate were analyzed. Results The mean clearance rate of 65 patients was (17.4±6.8)%. The efficacy of NCT was 86.2% (CR 4 cases, PR 52 cases, SD 8 cases, and PD 1 case), and the mean clearance rate of patients with good response or poor response of chemotherapy were (15.5±5.0)% and (29.2±3.2)%, respectively. There was a significant difference between the two groups. The average disease free survival rate in the group with low clearance rate was (75.8%,P=0.046), significantly higher than that in the group with high clearance rate (53. 1%). Conclusion Scintimammography of 99Tcm-MIBI may be used to evaluate the efficacy and prognosis of NCT for patients with operable breast cancer.